Multicenter Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Retreatment (Retreatment)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02984878 |
Recruitment Status :
Completed
First Posted : December 7, 2016
Results First Posted : December 20, 2017
Last Update Posted : December 20, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Nasolabial Fold Correction |
Intervention |
Device: Revanesse Ultra |
Enrollment | 71 |
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Revanesse Ultra Retreatment | Revanesse Ultra Optimal Correction |
---|---|---|
Arm/Group Description | Revanesse Ultra: Nasolabial Fold correction - - Subjects could have open-label retreatment as needed with Revanesse Ultra at 6 months if their WSRS scores had returned to baseline | The Optimal Correction group scores had not returned to baseline, subjects were eligible to be injected for either one or both NLFs as needed to achieve optimal correction (optimal correction group). |
Period Title: Overall Study | ||
Started | 30 | 41 |
Completed | 30 | 41 |
Not Completed | 0 | 0 |
Arm/Group Title | Revanesse Ultra Retreatment | Revanesse Ultra Optimal Correction | Total | |
---|---|---|---|---|
Arm/Group Description | Revanesse Ultra open label retreatment / Nasolabial Fold correction - optional open-label retreatment with Revanesse Ultra for subjects who had returned to baseline Wrinkle Severity Rating Scale (WSRS) score The subjects completing the initial phase of the SYM2014-02 study (NCT02987205) who had returned to baseline Wrinkle Severity Rating Scale (WSRS) score, were offered the option for retreatment with Revanesse Ultra Safety data was collected to assess treatment emergent adverse events associated with repeat injections. Seventy-one subjects received retreatment - 30 returned to baseline |
Revanesse Ultra open label retreatment / Nasolabial Fold correction - optional open-label retreatment with Revanesse Ultra for subjects as needed for optimal correction if WSRS scores had not returned to baseline. The subjects completing the initial phase of the SYM2014-02 study (NCT02987205) were treated as needed for optimal correction if WSRS scores had not returned to baseline, and were offered the option for retreatment with Revanesse Ultra Safety data was collected to assess treatment emergent adverse events associated with repeat injections. Seventy-one subjects received retreatment - 41 were included in the optimal correction group |
Total of all reporting groups | |
Overall Number of Baseline Participants | 30 | 41 | 71 | |
Baseline Analysis Population Description |
Revanesse Ultra open label retreatment / Nasolabial Fold correction - optional open-label retreatment with Revanesse Ultra for subjects who had returned to baseline Wrinkle Severity Rating Scale (WSRS) score or as needed for optimal correction if WSRS scores had not returned to baseline.
|
|||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 30 participants | 41 participants | 71 participants | |
58.3 (9.19) | 54.5 (10.44) | 56.1 (10.05) | ||
Age, Customized
[1] Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 30 participants | 41 participants | 71 participants |
22 to <40 years |
1 3.3%
|
5 12.2%
|
6 8.5%
|
|
40 to <64 years |
21 70.0%
|
27 65.9%
|
48 67.6%
|
|
64 to <75 years |
6 20.0%
|
9 22.0%
|
15 21.1%
|
|
> = 75 years |
2 6.7%
|
0 0.0%
|
2 2.8%
|
|
[1]
Measure Description: participants in each age group
|
||||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 30 participants | 41 participants | 71 participants | |
Female |
29 96.7%
|
37 90.2%
|
66 93.0%
|
|
Male |
1 3.3%
|
4 9.8%
|
5 7.0%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 30 participants | 41 participants | 71 participants | |
Hispanic or Latino |
4 13.3%
|
8 19.5%
|
12 16.9%
|
|
Not Hispanic or Latino |
26 86.7%
|
33 80.5%
|
59 83.1%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 30 participants | 41 participants | 71 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Asian |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
1 3.3%
|
4 9.8%
|
5 7.0%
|
|
White |
29 96.7%
|
37 90.2%
|
66 93.0%
|
|
More than one race |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
||||
United States | Number Analyzed | 30 participants | 41 participants | 71 participants |
30 100.0%
|
41 100.0%
|
71 100.0%
|
||
Fitzpatrick Skin Type (FST) Classification
[1] Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 30 participants | 41 participants | 71 participants |
FST I |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
FST II |
10 33.3%
|
17 41.5%
|
27 38.0%
|
|
FST III |
15 50.0%
|
15 36.6%
|
30 42.3%
|
|
FST IV |
3 10.0%
|
3 7.3%
|
6 8.5%
|
|
FST V |
1 3.3%
|
2 4.9%
|
3 4.2%
|
|
FST VI |
1 3.3%
|
4 9.8%
|
5 7.0%
|
|
[1]
Measure Description: FST Type I skin always burns, never tans (pale white; blond or red hair; blue, gray eyes; freckles), FST Type II skin usually burns, tans minimally (white; blond, brown or red hair; blue, green, or hazel eyes), FST Type III skin sometimes has a mild burn, tans uniformly (cream white; yellowish; any hair color or brown eyes), FST Type IV skin burns minimally, always tans well (light brown; olive; dark brown to black hair), FST Type V skin very rarely burns, tans very easily (brown), FST Type VI skin never burns, always tans (deeply pigmented dark brown to darkest brown, black in complexion)
|
Name/Title: | Ario Khoshbin, President |
Organization: | Prollenium Medical Technologies, Inc. |
Phone: | 866-353-3015 |
Responsible Party: | Prollenium Medical Technologies Inc. |
ClinicalTrials.gov Identifier: | NCT02984878 |
Other Study ID Numbers: |
SYM2014-02 Retreatment |
First Submitted: | December 5, 2016 |
First Posted: | December 7, 2016 |
Results First Submitted: | August 28, 2017 |
Results First Posted: | December 20, 2017 |
Last Update Posted: | December 20, 2017 |